Human Vaccines & Immunotherapeutics最新文献_第5页

Understanding barriers to influenza vaccination among parents is important to improve vaccine uptake among children.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-23 DOI: 10.1080/21645515.2025.2457198

Stephanie A Davey, James Elander, Amelia Woodward, Michael G Head, Daniel Gaffiero

{"title":"Understanding barriers to influenza vaccination among parents is important to improve vaccine uptake among children.","authors":"Stephanie A Davey, James Elander, Amelia Woodward, Michael G Head, Daniel Gaffiero","doi":"10.1080/21645515.2025.2457198","DOIUrl":"10.1080/21645515.2025.2457198","url":null,"abstract":"The COVID-19 pandemic has significantly altered public perceptions of vaccines, particularly among parents. In high-income countries like the United Kingdom (UK) and Australia, factors such as misinformation, the expedited approval process of COVID-19 vaccines and unique local challenges have contributed to vaccine hesitancy, resulting in uneven uptake across various vaccination programs. Despite efforts like school-based influenza vaccination programs in the UK and free influenza vaccines in Australia, vaccination rates continue to decline. This is especially concerning given the concurrent circulation of COVID-19 and influenza during the winter months, which places additional strain on healthcare systems. Drawing on existing evidence, this commentary examines key factors influencing childhood vaccination rates and provides preliminary policy recommendations to address these challenges. Three actionable recommendations are outlined, including strategies to counter misinformation, improve accessibility, and strengthen public trust in vaccination programs. These insights aim to guide the development of effective interventions to increase vaccination uptake.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2457198"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unreliable information and fear: Barriers to vaccination among IBD patients in China.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-24 DOI: 10.1080/21645515.2024.2446071

Jingwen Liu, Zelin Yan, Wen Hu, Shuyan Li, Yan Chen

{"title":"Unreliable information and fear: Barriers to vaccination among IBD patients in China.","authors":"Jingwen Liu, Zelin Yan, Wen Hu, Shuyan Li, Yan Chen","doi":"10.1080/21645515.2024.2446071","DOIUrl":"10.1080/21645515.2024.2446071","url":null,"abstract":"Vaccination plays a crucial role in safeguarding individuals with inflammatory bowel disease (IBD) from potential epidemics. In light of the resurgence of COVID-19 in China, unvaccinated IBD patients are vulnerable to infection and potentially serious complications. The aim of this study is to assess the vaccination uptake and willingness among IBD patients, as well as to explore the factors influencing their decision to decline vaccination. An online questionnaire was distributed and analyzed. Bivariate analyses and logistic regression models were used to identify relevant factors. Two hundred and three patients from 243 non-vaccinated respondents were included in the analysis. A total of 167 (82.3%) respondents continued to decline vaccination, with individuals holding stable employment and higher family income displaying significantly lower intent (p < .05). The primary factors contributing to their hesitancy were misinformation and apprehension regarding potential side effects. Obtaining vaccine information from online sources, particularly text-based content, and apprehensions surrounding the adverse effects of COVID-19 vaccination were also found to significantly diminish willingness to receive the vaccine (p < .01). The present study revealed that unreliable information about vaccines is a key factor of hesitancy among non-vaccinated IBD patients. Making efforts to spread true information about the COVID-19 vaccine is of great importance.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2446071"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-28 DOI: 10.1080/21645515.2025.2459458

Yan Zhang, Wenxuan Fan, Fei Su, Xiaoling Zhang, Yunyi Du, Weiling Li, Yangjun Gao, Wenqing Hu, Jun Zhao

{"title":"Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy.","authors":"Yan Zhang, Wenxuan Fan, Fei Su, Xiaoling Zhang, Yunyi Du, Weiling Li, Yangjun Gao, Wenqing Hu, Jun Zhao","doi":"10.1080/21645515.2025.2459458","DOIUrl":"10.1080/21645515.2025.2459458","url":null,"abstract":"Human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such as trastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. This review examines the mechanisms of drug resistance in HER2-positive G/GEJ cancer, the primary mechanisms of resistance explored include alterations in the HER2 receptor itself, such as mutations and changes in expression levels, as well as downstream signaling pathways, and interactions with the tumor microenvironment (TME). Furthermore, the review discusses the Novel therapeutic approaches, including the use of antibody-drug conjugates (ADCs) and combination therapies are assessed for their potential to enhance outcomes. By integrating recent research findings and clinical trials, this review aims to provide oncologists and researchers with insights into developing more effective treatments for patients with drug-resistant HER2-positive G/GEJ cancer.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2459458"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-02 DOI: 10.1080/21645515.2025.2458948

Jiayuan Le, Yuming Sun, Guangtong Deng, Yating Dian, Yanli Xie, Furong Zeng

{"title":"Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy.","authors":"Jiayuan Le, Yuming Sun, Guangtong Deng, Yating Dian, Yanli Xie, Furong Zeng","doi":"10.1080/21645515.2025.2458948","DOIUrl":"10.1080/21645515.2025.2458948","url":null,"abstract":"The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for patients with preexisting autoimmune diseases. Hence, we conducted a meta-analysis on safety and efficacy of ICIs in cancer patients with preexisting autoimmune diseases to provide further insights. PubMed, EMBASE, and Cochrane Library were systematically searched until December 20, 2024. The main summary measures used were pooled rate and risk ratio (RR) with 95% confidential interval (CI), which were analyzed using R statistic software. A total of 52 articles were included in the study. When cancer patients with preexisting autoimmune diseases received ICIs treatment, the overall incidence was 0.610 (95% CI: 0.531-0.686) for any grade irAEs, 0.295 (95% CI: 0.248-0.343) for flares, 0.325 (95% CI: 0.258-0.396) for de novo irAEs, 0.238 (95% CI: 0.174-0.309) for grade ≥3 irAEs, and 0.143 (95% CI: 0.109-0.180) for discontinuation due to immunotoxicity. Compared with those without autoimmune diseases, cancer patients with autoimmune diseases experienced a higher risk of any-grade irAEs (RR: 1.23, 95% CI: 1.12-1.35) and discontinuation due to immunotoxicity (1.40, 95% CI: 1.11-1.78). However, no statistically significant differences were observed in the incidence of grade ≥3 irAEs, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) between the two groups. During ICIs treatment, irAEs are common among cancer patients with autoimmune diseases, but severe irAEs is relatively low. ICIs are effective in this population, but should be strictly monitored when used to avoid immunotoxicity.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2458948"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-02 DOI: 10.1080/21645515.2025.2452681

Shiyuan Wang, Yang Zhang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Kai Chu, Jinfang Sun

{"title":"Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China.","authors":"Shiyuan Wang, Yang Zhang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Kai Chu, Jinfang Sun","doi":"10.1080/21645515.2025.2452681","DOIUrl":"10.1080/21645515.2025.2452681","url":null,"abstract":"Chickenpox outbreaks frequently occur in collective settings such as kindergartens and schools, posing a significant threat to children's physical and mental health. This study aimed to evaluate the immunogenicity and safety of the freeze-dried live attenuated varicella vaccine (VarV) developed by Beijing Minhai Biotechnology Co. LTD. in healthy participants aged 1-12 years. In this phase III, single-center, randomized, double-blind, active-controlled trial,1,200 healthy participants randomly assigned in a 1:1 ratio to receive one dose of either the test vaccine or the active control vaccine. Venous blood samples were collected before vaccination and 42 days after vaccination, and the fluorescent antibody to membrane antigen (FAMA) assay was used to detect VZV antibody. Adverse events (AEs) observed within 42 days after vaccination and serious adverse events (SAEs) within six months after vaccination were recorded. The seroconversion rates in the test and control groups were 96.79% and 96.43%, respectively, with a difference of 0.36% (95% CI, -1.76%-2.48%). The geometric mean titers (GMTs) were 61.74 and 58.04, respectively, with a difference of 1.06 (95% CI, 0.92-1.23). The lower limits of the 95% CI for the differences in seroconversion rates and GMT ratios between the two groups were greater than their respective pre-set non-inferiority margins. The overall incidence of AEs (p = .0112) in the test group was significantly lower than that in the control group. The freeze-dried live attenuated VarV developed by Beijing Minhai Biotechnology Co. LTD. demonstrated good immunogenicity and higher safety compared to the active control vaccine in healthy participants aged 1-12 years.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2452681"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-11 DOI: 10.1080/21645515.2025.2463191

Ariel Bardach, Martin Brizuela, Mabel Berrueta, Agustín Ciapponi, Juan M Sambade, Jamile Ballivian, Vanesa Ortega, Noelia Castellana, Daniel Comandé, Edward P K Parker, Beate Kampmann, Katharina Stegelmann, Xu Xiong, Andy Stergachis, Flor M Munoz, Pierre Buekens, Agustina Mazzoni

{"title":"Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.","authors":"Ariel Bardach, Martin Brizuela, Mabel Berrueta, Agustín Ciapponi, Juan M Sambade, Jamile Ballivian, Vanesa Ortega, Noelia Castellana, Daniel Comandé, Edward P K Parker, Beate Kampmann, Katharina Stegelmann, Xu Xiong, Andy Stergachis, Flor M Munoz, Pierre Buekens, Agustina Mazzoni","doi":"10.1080/21645515.2025.2463191","DOIUrl":"10.1080/21645515.2025.2463191","url":null,"abstract":"Chikungunya virus (CHIKV), transmitted through Aedes mosquitoes, is a significant global health concern. Various vaccine platforms have been explored to combat CHIKV, including formalin inactivation, live-attenuated strains, virus-like particles (VLPs), viral vectors, and mRNA technologies. This umbrella review synthesizes evidence on the safety profiles of vaccine platforms used in Chikungunya vaccines that have been applied in other vaccines, focusing on adverse events of special interest (AESI) in pregnant persons, children, and adolescents. A comprehensive overview of systematic reviews (SRs) was conducted. Results: Seven systematic reviews were included and complemented with primary studies. Vaccines like influenza, human papillomavirus (HPV), and COVID-19, which share platforms with Chikungunya vaccines, showed no significant increase in AESI. Moderate-to high-quality SRs supported favorable safety profiles. Vaccines sharing platforms with Chikungunya vaccines generally exhibit acceptable safety profiles in pregnant persons, children, and adolescents.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2463191"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is informed consent correctly obtained for vaccinations?

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-16 DOI: 10.1080/21645515.2025.2465116

Dhriti Jagadish, Nathaniel Mamo, Felicia Pasadyn, Arthur Caplan

{"title":"Is informed consent correctly obtained for vaccinations?","authors":"Dhriti Jagadish, Nathaniel Mamo, Felicia Pasadyn, Arthur Caplan","doi":"10.1080/21645515.2025.2465116","DOIUrl":"10.1080/21645515.2025.2465116","url":null,"abstract":"Informed consent is an integral tenet of medical ethics. However, the United States lacks a standardized consent process for immunizations, with states and private companies instead reliant on Vaccine Information Statements (VISs) introduced by the 1986 National Childhood Vaccine Injury Act. VISs, rather than being developed with patient autonomy in mind, were a response to excessive vaccine injury litigation and resulting vaccine supply shortages. VISs do not provide meaningful information disclosures, with its producer - the Centers for Disease Control and Prevention - itself admitting that VISs should not be mistaken for informed consent forms. In its content, the VIS is too complex in its readability, does not situate immunization in a public health context, and does not present all alternatives. VIS delivery is also inadequate, with limited time given for patients to digest vaccine information and no documentation required to ensure that VISs were presented at all. Simply put, VISs do little to spark deliberation and increase vaccine confidence. This article recommends minor improvements to VIS content, delivery, and accountability mechanisms to ensure distribution. The authors argue that these patient-provider moments - for patients to better understand their health, the threat of disease, and the weight of their contribution to the public - should not be squandered.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2465116"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-13 DOI: 10.1080/21645515.2025.2474772

Abby E Rudolph, Nadine Al Akoury, Natalija Bogdanenko, Kristen Markus, Isabelle Whittle, Olivia Wright, Hammam Haridy, Julia R Spinardi, John M McLaughlin, Moe H Kyaw

{"title":"Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review.","authors":"Abby E Rudolph, Nadine Al Akoury, Natalija Bogdanenko, Kristen Markus, Isabelle Whittle, Olivia Wright, Hammam Haridy, Julia R Spinardi, John M McLaughlin, Moe H Kyaw","doi":"10.1080/21645515.2025.2474772","DOIUrl":"10.1080/21645515.2025.2474772","url":null,"abstract":"This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020-July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for the relationship between COVID-19 vaccination and Post-COVID-19 Condition (PCC) by timing of vaccination relative to infection or PCC-onset. Comparisons of adjusted vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) across study characteristics known to impact PCC burden or VE against other COVID-19 endpoints were possible for 31 studies where vaccination preceded infection. Seventy-seven percent of pre-infection aVE estimates were statistically significant (range: 7%-95%). Statistically significant pre-infection aVE estimates were slightly higher for mRNA (range: 14%-84%) than non-mRNA vaccines (range: 16%-38%) and aVE ranges before and during Omicron overlapped. Our findings suggest that COVID-19 vaccination before SARS-CoV-2 infection reduces the risk of PCC regardless of vaccine type, number of doses received, PCC definition, predominant variant, and severity of acute infections included.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2474772"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanovaccine loaded with seno-antigen target senescent cells to improve metabolic disorders of adipose tissue and cardiac dysfunction.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-15 DOI: 10.1080/21645515.2025.2479229

Kexin Zhang, Qiliang Yin, Yucen Ma, Mengyu Cao, Lingwei Li, Xinliang Jin, Jiyan Leng

{"title":"Nanovaccine loaded with seno-antigen target senescent cells to improve metabolic disorders of adipose tissue and cardiac dysfunction.","authors":"Kexin Zhang, Qiliang Yin, Yucen Ma, Mengyu Cao, Lingwei Li, Xinliang Jin, Jiyan Leng","doi":"10.1080/21645515.2025.2479229","DOIUrl":"10.1080/21645515.2025.2479229","url":null,"abstract":"The buildup of senescent cells exacerbates metabolic disorders in adipose tissue and contributes to aging-related cardiac dysfunction. Targeted clearance of senescent cells can markedly ameliorate these aging-related diseases. Here, we developed a novel nanovaccine (GK-NaV) loaded with seno-antigen that is self-assembled from the fusion of cationic protein (K36) and seno-antigen peptide (Gpnmb). The GK-NaV could be highly engulfed by bone marrow-derived dendritic cells (BMDCs) and efficiently present antigens on the cellular surface, thereby promoting DCs maturation and activation of CD8+T cells in vitro. Following subcutaneous immunization, GK-NaV not only exhibited a noticeable antigen depot effect but also markedly activated specific cellular immune responses, enhancing the immunoreactivity and cytotoxic effects of CD8+T cells. Consequently, the targeted anti-aging immunity triggered by GK-NaV demonstrated the ability to selectively eliminate senescent adipocytes and cardiomyocytes in high-fat diet (HFD)-induced progeroid mice, leading to a significant improvement in age-related metabolic disorders in adipose tissue and cardiac dysfunction. Hence, our findings indicate that immunization with GK-NaV targeting seno-antigens may represent a promising strategy for novel senolytic therapies.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2479229"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season.

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-03-18 DOI: 10.1080/21645515.2025.2475616

Marina Amaral de Avila Machado, Sophie Gallo, Alexander Goldstein, Parth Vachhani, Reddappa Maniganahally Byrareddy, Anu Kantele, Hanna Välimaa, Jörg Schelling

{"title":"Enhanced passive safety surveillance of standard-dose and high-dose influenza vaccines in Finland and Germany 2023-24 season.","authors":"Marina Amaral de Avila Machado, Sophie Gallo, Alexander Goldstein, Parth Vachhani, Reddappa Maniganahally Byrareddy, Anu Kantele, Hanna Välimaa, Jörg Schelling","doi":"10.1080/21645515.2025.2475616","DOIUrl":"https://doi.org/10.1080/21645515.2025.2475616","url":null,"abstract":"Enhanced Passive Safety Surveillance was used to detect safety signals before the peak period of immunization with quadrivalent inactivated influenza vaccines (IIV4) in Finland (standard dose [SD]) and Germany (high dose [HD]) in the 2023-24 season. The primary objective was to evaluate adverse drug reactions (ADRs) occurring ≤7 days following IIV4 vaccination. Enrolled participants were vaccinated in routine clinical care settings and encouraged to report ADRs. Exposure data and ADR reports were collected in a near real-time manner using an electronic system. Vaccinee reporting rate (RR) with 95% confidence interval (CI) was calculated as the number of vaccinees reporting ≥ 1 ADR divided by total number of vaccinees. In Finland for SD-IIV4, among 1,003 vaccinees aged ≥ 6 months, 81 reported a total of 192 suspected ADRs occurring ≤ 7 days following vaccination (vaccinee RR 8.08%; 95% CI 6.46, 9.94). In Germany for HD-IIV4, among 1,075 vaccinees aged ≥ 60 years, 15 reported 46 ADRs that occurred in ≤ 7 days of vaccination (vaccinee RR 1.40%; 95% CI 0.78, 2.29). No safety signal was detected during this surveillance. The 2023-24 season surveillance did not suggest any clinically significant changes in safety profile compared with previously reported safety data for SD-IIV4 and HD-IIV4.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2475616"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0